Compare uniQure N.V. Ordinary Shares (QURE) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B), while Royalty Pharma plc Class A Ordinary Shares trades at $59.03 (market cap $25.18B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 17× uniQure N.V. Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 6 Days on average.
| QURE | RPRX | |
|---|---|---|
Market Cap | $1.48B | $25.18B |
Volume | 2,488,780 | 3,399,248 |
Sector | Health | Health |
52-Week High | $70.59 | $63.96 |
52-Week Low | $9.03 | $36.18 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $728.62M | $32.42B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Royalty Pharma (RPRX) trades at $56.57, down 2.09% on the day, with a bullish technical signal and strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue and net income show steady growth, supported by a high gross profit margin of 89.38%. Analyst consensus is unanimously bullish with a $63.33 price target.
The outlook remains positive given earnings momentum and strategic capital deployment, though risks include biopharma policy shifts and reliance on partner drug performance. The stock offers exposure to a diversified portfolio of blockbuster drugs with minimal operational risk, but investors should monitor upcoming earnings and broader sector dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
